Udvalget for Humanmedicinske Lægemidler (CHMP) konkluderede, at fordelene ved QUADRAMET er større end risiciene ved lindring af knoglesmerter hos patienter med multiple smertefulde osteoblastiske knoglemetastaser.
The Committee for Medicinal Products for Human Use (CHMP) decided that QUADRAMET’ s benefits are greater than its risks for the relief of bone pain in patients with multiple painful osteoblastic skeletal metastases.